PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.

Dermot O'Toole Pamela L Kunz Susan M Webb Grace Goldstein Sheila Khawaja Mark McDonnell Sandra Boiziau Delphine Gueguen Aude Houchard Antonio Ribeiro-Oliveira Junior Ally Prebtani

Published in: Advances in therapy (2022)

Compared with OCT, significantly fewer patients using LAN had injection-site pain lasting > 2 days after their most recent injection. Also, fewer LAN-treated patients experienced technical problems during injection. These findings demonstrate the importance of injection modality for overall LA SSA injection experience for patients with acromegaly or NETs.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes
cross sectional